Severe haematological complications during treatment with natalizumab

Abstract

The safety profile of natalizumab has been widely discussed due to several cases of progressive multifocal leukoencephalopathy, reported worldwide. Since the launch of natalizumab, 32 patients have been treated at our centre. In this context, we describe two cases (6.25%), one of immune-mediated acute haemolytic anaemia (IAHA) and another of immune thrombocytopenic purpura during treatment with natalizumab. The temporal relationship between drug administration and the nature of the haematological complications, confirmed with the serological findings in the case of the IAHA, suggests that natalizumab is the most probable cause for these adverse events. Although very uncommon, the haematological complications are severe enough to justify a close and careful monitoring for all patients with multiple sclerosis treated with an immunosuppressant treatment.

Keywords

demyelination disease-modifying therapies

Get full access to this article

View all access options for this article.

References

Polman

O’Connor

Havrdova

. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Rudick

Stuart

Calabresi

. A randomized, placebo-controlled trial of natalizumab plus interferon beta-1^a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–923.

Goodin

Cohen

O’Connor

. Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Neurology 2008; 71: 766–773.

Kappos

Bates

Hartung

. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6: 431–441.

Stosic

De Jesus

McCarthy

. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology 2011; 77: 505–507.

Garratty

. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2009: 73–79.

Arndt

Garratty

. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol 2005; 42: 137–144.

George

Aster

. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program 2009: 153–158.

CAMMS223 Trial Investigators, Coles

Compston

. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–1801.